Riskpilot← Back to searchSign inGet full accessContrivex AB
ABActiveOrg 5591334239Vrängövägen 2General medical practice activities · NACE 8621Est. 20170 employees
Revenue 2024
SEK 695K
-18% vs 2023
EBITDA margin
48.5%
-42% vs 2023
Equity ratio
60.2%
Financial strength
Net profit 2024
SEK 368K
+1% vs 2023
| Revenue | SEK 695K | -18% |
| EBITDA | SEK 337K | -42% |
| Net profit | SEK 368K | +1% |
| Total assets | SEK 2,9M | +0% |
| Equity | SEK 1,8M | +10% |
| Employees | 0 | — |
Legal name
Contrivex AB
Org number
5591334239
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
13 november 2017
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva konsultation inom företrädesvis radiologisk sjukhusfysik, äga och förvalta värdepapper och fastigheter samt därmed förenlig verksamhet.
Address
Vrängövägen 2
Email
erik.jurvin@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 064 | 934 | 1 110 | 844 | 695 |
| Staff expenses | — | — | −75 | −43 | −189 |
| EBITDA | 801 | 668 | 736 | 581 | 337 |
| Depreciation & amort. | −7 | −7 | −7 | −3 | — |
| EBIT | 794 | 661 | 729 | 578 | 337 |
| Net financials | −2 | −3 | 3 | 47 | 85 |
| Profit before tax | 594 | 497 | 548 | 465 | 475 |
| Tax | −128 | −103 | −114 | −100 | −107 |
| Net profit | 466 | 394 | 433 | 365 | 368 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 759 | 2 104 | 2 564 | 2 916 | 2 921 |
| Equity | 970 | 1 181 | 1 426 | 1 596 | 1 760 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 144 | 111 | 142 | 165 | 58 |
| Total debt | 144 | 111 | 142 | 165 | 58 |
EBITDA margin
48.5%
This company
15.8%
Market median
+207% vs market
20202024
Equity ratio
60.2%
This company
38.2%
Market median
+58% vs market
20202024
Return on equity
20.9%
This company
18.4%
Market median
+14% vs market
20202024
Net profit margin
52.9%
This company
8.1%
Market median
+553% vs market
20202024
Asset turnover
0.24×
This company
1.12×
Market median
-79% vs market
20202024
Debt / equity
0.66×
This company
0.62×
Market median
+6% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EO Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Contrivex AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Olov Jurvin | Chief Executive Officer | 0 companies |
| Per Magnus Jurvin | Deputy Board Member | 0 companies |